QQQ   356.96 (+0.65%)
AAPL   184.68 (+2.06%)
MSFT   337.84 (+0.73%)
META   273.05 (+0.16%)
GOOGL   126.97 (+1.84%)
AMZN   125.00 (+0.60%)
TSLA   218.29 (+2.02%)
NVDA   391.33 (-0.49%)
NIO   7.75 (+2.51%)
BABA   83.94 (-0.39%)
AMD   118.14 (+0.24%)
T   15.33 (+0.79%)
F   12.65 (+2.10%)
MU   68.23 (-1.36%)
CGC   0.79 (-4.58%)
GE   104.80 (-0.95%)
DIS   90.13 (-0.71%)
AMC   4.61 (+1.32%)
PFE   38.75 (+1.02%)
PYPL   64.63 (+1.05%)
NFLX   411.53 (+2.76%)
QQQ   356.96 (+0.65%)
AAPL   184.68 (+2.06%)
MSFT   337.84 (+0.73%)
META   273.05 (+0.16%)
GOOGL   126.97 (+1.84%)
AMZN   125.00 (+0.60%)
TSLA   218.29 (+2.02%)
NVDA   391.33 (-0.49%)
NIO   7.75 (+2.51%)
BABA   83.94 (-0.39%)
AMD   118.14 (+0.24%)
T   15.33 (+0.79%)
F   12.65 (+2.10%)
MU   68.23 (-1.36%)
CGC   0.79 (-4.58%)
GE   104.80 (-0.95%)
DIS   90.13 (-0.71%)
AMC   4.61 (+1.32%)
PFE   38.75 (+1.02%)
PYPL   64.63 (+1.05%)
NFLX   411.53 (+2.76%)
QQQ   356.96 (+0.65%)
AAPL   184.68 (+2.06%)
MSFT   337.84 (+0.73%)
META   273.05 (+0.16%)
GOOGL   126.97 (+1.84%)
AMZN   125.00 (+0.60%)
TSLA   218.29 (+2.02%)
NVDA   391.33 (-0.49%)
NIO   7.75 (+2.51%)
BABA   83.94 (-0.39%)
AMD   118.14 (+0.24%)
T   15.33 (+0.79%)
F   12.65 (+2.10%)
MU   68.23 (-1.36%)
CGC   0.79 (-4.58%)
GE   104.80 (-0.95%)
DIS   90.13 (-0.71%)
AMC   4.61 (+1.32%)
PFE   38.75 (+1.02%)
PYPL   64.63 (+1.05%)
NFLX   411.53 (+2.76%)
QQQ   356.96 (+0.65%)
AAPL   184.68 (+2.06%)
MSFT   337.84 (+0.73%)
META   273.05 (+0.16%)
GOOGL   126.97 (+1.84%)
AMZN   125.00 (+0.60%)
TSLA   218.29 (+2.02%)
NVDA   391.33 (-0.49%)
NIO   7.75 (+2.51%)
BABA   83.94 (-0.39%)
AMD   118.14 (+0.24%)
T   15.33 (+0.79%)
F   12.65 (+2.10%)
MU   68.23 (-1.36%)
CGC   0.79 (-4.58%)
GE   104.80 (-0.95%)
DIS   90.13 (-0.71%)
AMC   4.61 (+1.32%)
PFE   38.75 (+1.02%)
PYPL   64.63 (+1.05%)
NFLX   411.53 (+2.76%)
NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Competitors

$91.77
-1.59 (-1.70%)
(As of 01:16 PM ET)
Compare
Today's Range
$90.75
$93.49
50-Day Range
$86.94
$100.30
52-Week Range
$70.73
$117.77
Volume
534,322 shs
Average Volume
1.34 million shs
Market Capitalization
$17.23 billion
P/E Ratio
241.50
Dividend Yield
N/A
Price Target
$118.65

BMRN vs. UTHR, ALNY, IONS, MDGL, ALKS, SRPT, VTRS, BGNE, LEGN, and APLS

Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include United Therapeutics (UTHR), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Viatris (VTRS), BeiGene (BGNE), Legend Biotech (LEGN), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.

BioMarin Pharmaceutical vs.

BioMarin Pharmaceutical (NASDAQ:BMRN) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.

BioMarin Pharmaceutical has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

BioMarin Pharmaceutical received 970 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 75.17% of users gave BioMarin Pharmaceutical an outperform vote while only 60.59% of users gave United Therapeutics an outperform vote.

CompanyUnderperformOutperform
BioMarin PharmaceuticalOutperform Votes
1508
75.17%
Underperform Votes
498
24.83%
United TherapeuticsOutperform Votes
538
60.59%
Underperform Votes
350
39.41%

BioMarin Pharmaceutical presently has a consensus price target of $118.65, suggesting a potential upside of 20.16%. United Therapeutics has a consensus price target of $294.67, suggesting a potential upside of 35.65%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than BioMarin Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical
1 Sell rating(s)
7 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.53
United Therapeutics
2 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.56

United Therapeutics has lower revenue, but higher earnings than BioMarin Pharmaceutical. United Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$2.10 billion8.26$141.56 million$0.38242.63
United Therapeutics$1.94 billion5.25$727.30 million$14.8514.61

United Therapeutics has a net margin of 36.76% compared to BioMarin Pharmaceutical's net margin of 3.30%. United Therapeutics' return on equity of 15.49% beat BioMarin Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical 3.30% 4.02% 2.92%
United Therapeutics 36.76% 15.49% 12.28%

In the previous week, BioMarin Pharmaceutical and BioMarin Pharmaceutical both had 8 articles in the media. United Therapeutics' average media sentiment score of 1.12 beat BioMarin Pharmaceutical's score of 0.90 indicating that United Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioMarin Pharmaceutical
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
United Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.3% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 95.6% of United Therapeutics shares are owned by institutional investors. 1.8% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 12.5% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

United Therapeutics beats BioMarin Pharmaceutical on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRN vs. The Competition

MetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$17.31B$5.71B$4.45B$6.26B
Dividend YieldN/A2.61%5.95%6.50%
P/E Ratio242.634.0182.7311.17
Price / Sales8.26325.943,368.0487.37
Price / Cash63.3720.1522.0023.57
Price / Book3.714.974.735.53
Net Income$141.56M$186.08M$115.49M$192.15M
7 Day Performance4.19%8.02%121.56%9.32%
1 Month Performance-4.58%5.63%123.55%11.03%
1 Year Performance18.98%18.94%135.83%1.57%

BioMarin Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTHR
United Therapeutics
3.1987 of 5 stars
$205.19
-1.0%
$294.67
+43.6%
-5.0%$9.61B$1.94B13.82965Positive News
ALNY
Alnylam Pharmaceuticals
2.4537 of 5 stars
$186.46
-1.0%
$247.20
+32.6%
+47.3%$23.22B$1.04B-21.462,002Analyst Revision
IONS
Ionis Pharmaceuticals
1.6504 of 5 stars
$40.55
-0.5%
$46.64
+15.0%
+15.5%$5.80B$587M-17.55660
MDGL
Madrigal Pharmaceuticals
2.2897 of 5 stars
$280.02
-1.7%
$312.36
+11.6%
+262.8%$5.12BN/A-15.4771Analyst Downgrade
ALKS
Alkermes
1.6335 of 5 stars
$29.18
-0.5%
$31.67
+8.5%
+0.7%$4.85B$1.11B-29.472,280
SRPT
Sarepta Therapeutics
2.7122 of 5 stars
$124.82
-1.6%
$169.65
+35.9%
+71.5%$11.63B$933.01M-9.841,162
VTRS
Viatris
2.8856 of 5 stars
$9.18
+0.8%
$12.67
+38.0%
-20.3%$11.01B$16.26B5.8537,000
BGNE
BeiGene
2.2164 of 5 stars
$228.27
-3.6%
$289.16
+26.7%
+60.2%$21.84B$1.42B-12.299,200Positive News
LEGN
Legend Biotech
1.8315 of 5 stars
$64.08
+1.5%
$77.40
+20.8%
+37.8%$10.58B$117M0.001,390Positive News
APLS
Apellis Pharmaceuticals
1.5927 of 5 stars
$86.91
-0.1%
$90.93
+4.6%
+93.2%$10.12B$105.89M-13.86476Insider Selling

Related Companies and Tools

This page (NASDAQ:BMRN) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -